Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chugai Pharma Approved for China Launch of Complement Inhibitor 5 for NPH

publication date: Feb 13, 2024

Tokyo’s Chugai Pharma announced China approval of crovalimab, a humanized complement inhibitor C5 mAb to treat paroxysmal nocturnal hemoglobinuria (PNH).  It is the first approval of crovalimab anywhere in the world. A rare disease, PNH is an acquired life-threatening blood disease, characterized by the destruction of red blood cells, blood clots and impaired bone marrow function. Crovalimab uses Chugai’s Recycling Antibody technology, which allows a mAb to bind repeatedly to an antigen, enabling sustained complement inhibition at a low dose. Switzerland’s Roche owns 62% of Chugai. More details....

See our other articles on Chugai.

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital